Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RAPT
DateTimeSourceHeadlineSymbolCompany
09/05/202413:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202417:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202421:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202421:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
22/02/202422:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202412:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202413:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202413:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202316:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202316:00GlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
01/11/202320:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberNASDAQ:RAPTRAPT Therapeutics Inc
23/10/202321:40Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RAPTRAPT Therapeutics Inc
18/10/202314:00GlobeNewswire Inc.RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
30/08/202321:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in SeptemberNASDAQ:RAPTRAPT Therapeutics Inc
18/08/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RAPTRAPT Therapeutics Inc
11/08/202321:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
11/08/202313:57Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
11/08/202313:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RAPT